BOSTON, June 17, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Aerovate Therapeutics, Inc. (NASDAQ:AVTE) for potential securities law violations. Investors who have lost money in their Aerovate Therapeutics investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/avte.
What is this all about?
Shares of Aerovate Therapeutics are down 90.1% following the release of poor top line results from its Phase 2b portion of IMPAHCT evaluating AV-101 for the treatment of pulmonary arterial hypertension. Block & Leviton is investigating whether the Company violated any securities laws in the lead up to this announcement.
Who is eligible?
Anyone who purchased Aerovate Therapeutics common stock and has seen their shares ...